Thioredoxin reductase and its inhibitors

Current Protein and Peptide Science

Volumn 15, Issue 6, 2014, Pages 621-646

  Saccoccia, Fulvio ^a   Angelucci, Francesco ^b   Boumis, Giovanna ^a   Carotti, Daniela ^a   Desiato, Gianni ^a   Miele, Adriana E ^a   Bellelli, Andrea ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Competitive inhibitor; Double substrate enzyme; Irreversible inhibitor; Mechanism of inhibition; Pseudo irreversible inhibition; Suicide substrates; Thioredoxin reductase; Uncompetitive inhibitor

Indexed keywords

3 4 DIHYDROQUINAZOLINE DERIVATIVE; 9 10 PHENANTRENE QUINONE; ALKYLATING AGENT; ANTIMONY TARTRATE; ARSENIC TRIOXIDE; AURANOFIN; AZELAIC ACID; CARBOPLATIN; CURCUMIN; ENZYME INHIBITOR; EPIGALLOCATECHIN GALLATE; FLAVOPROTEIN; GOLD CYANIDE; MERCURIC CHLORIDE; METAL ION; N BUTYL 2 IMIDAZOLYL DISULFIDE; N DECYL 2 IMIDAZOLYL DISULFIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; NITROSOUREA; ORGANOTELLURIUM DERIVATIVE; OXALIPLATIN; OXIDOREDUCTASE INHIBITOR; PEROXYNITRITE; PROTOPORPHYRIN; QUINAZOLINE DERIVATIVE; THIOREDOXIN REDUCTASE; THIOREDOXIN REDUCTASE INHIBITOR; UNCLASSIFIED DRUG; 1 METHYLPROPYL 2 IMIDAZOLYL DISULFIDE; 3, 4 DIHYDROXYBENZYLAMINE; 3,4 DIHYDROQUINAZOLINE DERIVATIVE; 9,10 PHENANTRENE QUINONE; AUROTHIOMALATE; CARMUSTINE; DIARYLPIRROLE (4 ((1 (4 ETHYLPHENYL) 2 METHYL 5 (4 (METHYLTHIO)PHENYL) 1H PYRROL 3 YL)METHYL)THIOMORPHOLINE); FLAVINE ADENINE NUCLEOTIDE; METAL COMPLEX; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SILVER NANOPARTICLE; PROTEIN BINDING;

BINDING AFFINITY; CATALYSIS; COMPETITIVE INHIBITION; COVALENT BOND; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME BINDING; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME KINETICS; ENZYME MECHANISM; ENZYME SUBSTRATE; IC 50; NONCOMPETITIVE INHIBITION; OXIDATION REDUCTION REACTION; PROTEIN FOLDING; REVIEW; SUICIDE SUBSTRATE; ARTICLE; CRYSTAL STRUCTURE; CRYSTALLIZATION; ENZYME STRUCTURE; HUMAN; IC50; INCUBATION TIME; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; TRYPANOSOMA; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; KINETICS; METABOLISM; PROTEIN CONFORMATION;

ANIMALS; ENZYME INHIBITORS; HUMANS; KINETICS; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN CONFORMATION; THIOREDOXIN-DISULFIDE REDUCTASE;

EID: 84906900036     PISSN: 13892037     EISSN: 18755550     Source Type: Journal    
DOI: 10.2174/1389203715666140530091910     Document Type: Review

References (113)

1. Holmgren, A.; Lu, J. Thioredoxin and thioredoxin reductase: current research with special reference to human disease. Biochem. Biophys. Res. Commun., 2010 396, 120-124.
2. Arnér, E.S. Focus on mammalian thioredoxin reductases-important selenoproteins with versatile functions. Biochim. Biophys. Acta., 2009 1790, 495-526.
3. Hirt, R.P.; Müller, S.; Embley, T.M.; Coombs, G.H. The diversity and evolution of thioredoxin reductase: new perspectives. Trends Parasitol., 2002 18, 302-308.
4. Prast-Nielsen, S.; Huang, H.H.; Williams, D.L. Thioredoxin glutathione reductase: its role in redox biology and potential as a target for drugs against neglected diseases. Biochim. Biophys. Acta, 2011 1810, 1262-1271.
5. Cioli, D.; Valle, C.; Angelucci, F.; Miele, A.E. Will new antischistosomal drugs finally emerge? Trends Parasitol., 2008, 24, 379-382.
6. Williams, D.L.; Bonilla, M.; Gladyshev, V.N.; Salinas, G. Thioredoxin glutathione reductase-dependent redox networks in platyhelminth parasites. Antioxid Redox Signal., 2013 19, 735-745.
7. Tonissen, K.F.; Di Trapani. G. Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy. Mol. Nutr. Food Res., 2009 53, 87-103.
8. Selenius, M.; Rundlof, A.K.; Olm, E.; Fernandes, A.P.; Bjornstedt, M. Selenium and the selenoprotein thioredoxin reductase in the prevention, treatment and diagnostics of cancer. Antioxid. Redox Signal., 2010 12, 867-880.
9. Boumis, G.; Giardina, G.; Angelucci, F.; Bellelli, A.; Brunori, M.; Dimastrogiovanni, D.; Saccoccia, F.; Miele, A.E. Crystal structure of Plasmodium falciparum thioredoxin reductase, a validated drug target. Biochem. Biophys. Res. Commun., 2012 425, 806-811.
10. Saccoccia, F.; Di Micco, P.; Boumis, G.; Brunori, M.; Koutris, I.; Miele, A.E.; Morea, V.; Sriratana, P.; Williams, D.L.; Bellelli, A.; Angelucci, F. Moonlighting by different stressors: crystal structure of the chaperone species of a 2-Cys peroxiredoxin. Structure, 2012 20, 429-439.
11. Becker, K.; Gromer, S.; Schirmer, R.H.; Muller, S. Thioredoxin reductase as a pathophysiological factor and drug target. Eur. J. Biochem., 2000 267, 6118-6125.
12. Cimini, A.; Gentile, R.; Angelucci, F.; Benedetti, E.; Pitari, G.; Giordano, A.; Ippoliti, R. Neuroprotective effects of PrxI overexpression in an in vitro human Alzheimer's disease model. J. Cell Biochem., 2013 114, 708-715.
13. Cai, W.; Zhang, L.; Song, Y.; Wang, B.; Zhang, B.; Cui, X.; Hu, G.; Liu, Y.; Wu, J.; Fang J. Small molecule inhibitors of mammalian thioredoxin reductase. Free Radic. Biol. Med., 2012 52, 257-265.
14. Kuntz, A.N.; Davioud-Charvet, E.; Sayed, A.A.; Califf, L.L.; Dessolin, J.; Arnér, E.S.; Williams, D.L. Thioredoxin glutathione reductase from Schistosoma mansoni: an essential parasite enzyme and a key drug target. PLoS Med., 2007 4, e206.
15. Sannella, A.R.; Casini, A.; Gabbiani, C.; Messori, L.; Bilia, A.R.; Vincieri, F.F.; Majori, G.; Severini, C. New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects in vitro: Mechanistic and pharmacological implications. FEBS Lett., 2008 582, 844-847.
16. Angelucci, F.; Miele, A.E.; Boumis, G.; Brunori, M.; Dimastrogiovanni, D.; Bellelli, A. Macromolecular bases of antischistosomal therapy. Curr. Top. Med. Chem., 2011 11, 2012-2028.
17. Casini, A.; Messori, L. Molecular mechanisms and proposed targets for selected anticancer gold compounds. Curr. Top. Med. Chem., 2011 11, 2647-2660.
18. Angelucci, F.; Dimastrogiovanni, D.; Boumis, G.; Brunori, M.; Miele, A.E.; Saccoccia, F.; Bellelli, A. Mapping the catalytic cycle of Schistosoma mansoni thioredoxin glutathione reductase by Xray crystallography. J. Biol. Chem., 2010 285, 32557-32567.
19. Paz, M.M.; Zhang, X.; Lu, J.; Holmgren, A. A new mechanism of action for the anticancer drug mitomycin C: mechanism-based inhibition of thioredoxin reductase. Chem. Res. Toxicol., 2012 25, 1502-1511.
20. Angelucci, F.; Sayed, A.A.; Williams, D.L.; Boumis, G.; Brunori, M.; Dimastrogiovanni, D.; Miele, A.E.; Pauly, F.; Bellelli, A. Inhibition of Schistosoma mansoni thioredoxin-glutathione reductase by auranofin: structural and kinetic aspects. J. Biol. Chem., 2009 284, 28977-28985.
21. Saccoccia, F.; Angelucci, F.; Boumis, G.; Brunori, M.; Miele, A.E.; Williams, D.L.; Bellelli, A. On the mechanism and rate of gold incorporation into thiol-dependent flavoreductases. J. Inorg. Biochem., 2012 108, 105-111.
22. Urig, S.; Becker, K. On the potential of thioredoxin reductase inhibitors for cancer therapy. Semin. Cancer Biol., 2006 16, 452-465.
23. Sandalova, T.; Zhong, L.; Lindqvist, Y.; Holmgren, A.; Schneider, G. Three-dimensional structure of a mammalian thioredoxin reductase: implications for mechanism and evolution of a selenocysteinedependent enzyme. Proc. Natl. Acad. Sci. U. S. A., 2001 98, 9533-9538.
24. Rao, S.T.; Rossmann, M.G. Comparison of super-secondary structures in proteins. J. Mol. Biol., 1973 76, 241-256.
25. Lothrop, A.P.; Ruggles, E.L.; Hondal, R.J. No selenium required: Reactions catalyzed by mammalian thioredoxin reductase that are independent of a selenocysteine residue. Biochemistry, 2009 48, 6213-6223.
26. Tamura, T.; Stadtman, T.C. A new selenoprotein from human lung adenocarcinoma cells: purification, properties, and thioredoxin reductase activity. Proc. Natl. Acad. Sci. U. S. A., 1996 93, 1006-1011.
27. Arscott, L.D.; Gromer, S.; Schirmer, R.H.; Becker, K.; Williams, C.H. Jr. The mechanism of thioredoxin reductase from human placenta is similar to the mechanisms of lipoamide dehydrogenase and glutathione reductase and is distinct from the mechanism of thioredoxin reductase from Escherichia coli. Proc. Natl. Acad. Sci. U. S. A., 1997, 94, 3621-3626.
28. Fritz-Wolf, K.; Urig, S.; Becker, K. The structure of human thioredoxin reductase 1 provides insights into C-terminal rearrangements during catalysis. J. Mol. Biol., 2007 370, 116-127.
29. Gasdaska, P.Y.; Gasdaska, J.R.; Cochran, S.; Powis, G. Cloning and sequencing of a human thioredoxin reductase. FEBS Lett., 1995 373, 5-9.
30. Russel, M.; Model, P. Sequence of thioredoxin reductase from Escherichia coli. Relationship to other flavoprotein disulfide oxidoreductases. J. Biol. Chem., 1988 263, 9015-9019.
31. Stoll, V.S.; Simpson, S.J.; Krauth-Siegel, R.L.; Walsh, C.T.; Pai, E.F. Glutathione reductase turned into trypanothione reductase: structural analysis of an engineered change in substrate specificity. Biochemistry, 1997 36, 6437-6447.
32. Angelucci, F.; Miele, A.E.; Boumis, G.; Dimastrogiovanni, D.; Brunori, M.; Bellelli, A. Glutathione reductase and thioredoxin reductase at the crossroad: the structure of Schistosoma mansoni thioredoxin glutathione reductase. Proteins, 2008 72, 936-945.
33. Urig, S.; Lieske, J.; Fritz-Wolf, K.; Irmler, A.; Becker, K. Truncated mutants of human thioredoxin reductase 1 do not exhibit glutathione reductase activity. FEBS Lett., 2006 580, 3595-3600.
34. Hondal, R.J. Using chemical approaches to study selenoproteinsfocus on thioredoxin reductases. Biochim. Biophys. Acta, 2009 1790, 1501-1512.
35. Patterson, S.; Alphey, M.S.; Jones, D.C.; Shanks, E.J.; Street I.P.; Frearson, J.A.; Wyatt, P.G.; Gilbert, I.H.; Fairlamb, A.H. Dihydroquinazolines as a novel class of Tripanosoma brucei trypanothione reductase inhibitors: discovery, synthesis, and characterization of their binding mode by protein crystallography. J. Med. Chem., 2011 54, 6514-6530.
36. Savvides, S.N.; Karplus, P.A. Kinetics and Crystallographic Analysis of Human Glutathione Reductase in Complex with a Xanthene Inhibitor. J. Biol. Chem., 1996 271, 8101-8107.
37. Bauer, H.; Gromer, S.; Urbani, A.; Schnölzer, M,; Schirmer, R.H.; Müller, H.M. Thioredoxin reductase from the malaria mosquito Anopheles gambiae. Eur. J. Biochem., 2003 270, 4272-4281.
38. Cheng, Y.C.; Prusoff, W.H. Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol., 1973 22, 3099-3108.
39. Copeland, R.A. Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis, 2nd ed.; Wiley-VCH, 2000.
40. Schallreuter, K.U.; Gleason, F.K.; Wood, J.M. The mechanism of action of the nitrosourea anti-tumor drugs on thioredoxin reductase, glutathione reductase and ribonucleotide reductase. Biochim. Biophys. Acta, 1990 1054, 14-20.
41. Chen, G.P.; Raybuck, S.; Ziegler, D.M. Flavoenzymes inhibited by indomethacin. Drug Metabol. Drug Interact., 1994 11, 153-160.
42. Streitenberger, S.A.; López-Mas, J.A.; Sánchez-Ferrer, A.; García-Carmona, F. Non-linear slow-binding inhibition of Aerococcus viridans lactate oxidase by Cibacron Blue 3GA. J. Enzyme Inhib., 2001 16, 301-312.
43. Prast-Nielsen, S.; Dexheimer, T.S.; Schultz, L.; Stafford, W.C.; Cheng, Q.; Xu, J.; Jadhav, A.; Arnér, E.S.; Simeonov, A. Inhibition of thioredoxin reductase 1 by porphyrins and other small molecules identified by a high-throughput screening assay. Free Radic. Biol. Med., 2011 50, 1114-1123.
44. Wang, Y.; Zhang, H.; Holmgren, A.; Tian, W.; Zhong, L. Inhibitory effect of green tea extract and (-)-epigallocatechin-3-gallate on mammalian thioredoxin reductase and HeLa cell viability. Oncol. Rep., 2008 20, 1479-1487.
45. Lin, S.; Cullen, W.R.; Thomas, D.J. Methylarsenicals and arsinothiols are potent inhibitors of mouse liver thioredoxin reductase. Chem. Res. Toxicol., 1999 12, 924-930.
46. Tibodeau, J.D.; Benson, L.M.; Isham, C.R.; Owen, W.G.; Bible, K.C. The anticancer agent chaetocin is a competitive substrate and inhibitor of thioredoxin reductase. Antioxid. Redox Signal., 2009 11, 1097-1106.
47. Benson, T.J.; McKie, J.H.; Garforth, J.; Borges, A.; Fairlamb, A.H.; Douglas, K.T. Rationally designed selective inhibitors of trypanothione reductase. Phenothiazines and related tricyclics as lead structures. Biochem. J., 1992 286, 9-11.
48. Chan, C.; Yin, H.; Garforth, J.; McKie, J.H.; Jaouhari, R.; Speers, P.; Douglas, K.T.; Rock, P.J.; Yardley, V.; Croft, S.L.; Fairlamb, A.H. Phenothiazine inhibitors of trypanothione reductase as potential antitrypanosomal and antileishmanial drugs. J Med Chem. 1998, 41, 148-156. Erratum in: J. Med. Chem., 1998 41, 4910.
49. Garrard, E.A.; Borman, E.C.; Cook, B.N.; Pike, E.J.; Alberg, D.G. Inhibition of trypanothione reductase by substrate analogues. Org. Lett., 2000 2, 3639-3642.
50. Oblong, J.E.; Chantler, E.L.; Gallegos, A.; Kirkpatrick, D.L.; Chen, T.; Marshall, N.; Powis, G. Reversible inhibition of human thioredoxin reductase activity by cytotoxic alkyl 2-imidazolyl disulfide analogues. Cancer Chemother. Pharmacol., 1994 34, 434-438.
51. Cenas, N.; Nivinskas, H.; Anusevicius, Z; Sarlauskas, J.; Lederer, F.; Arnér, E.S. Interactions of quinones with thioredoxin reductase: a challenge to the antioxidant role of the mammalian selenoprotein. J. Biol. Chem., 2004 279, 2583-2592.
52. Baiocco, P.; Poce, G.; Alfonso, S; Cocozza, M; Porretta, G.C.; Colotti, G.; Biava, M.; Moraca, F.; Botta, M.; Yardley, V.;, Fiorillo, A.; Lantella, A.; Malatesta F.; Ilari, A. Inhibition of Leishmania infantum trypanothione reductase by azole-based compounds: a comparative analysis with its physiological substrate by X-ray crystallography. ChemMedChem., 2013 8, 1175-1183.
53. Kasozi, D.M.; Gromer, S.; Adler, H.; Zocher, K.; Rahlfs, S.; Wittlin, S.; Fritz-Wolf, K.; Schirmer R.H.; Becker, K. The bacterial redox signaller pyocyanin as an antiplasmodial agent: comparisons with its thioanalog methylene blue. Redox Rep., 2011 16, 154-165.
54. Simeonov, A.; Jadhav, A.; Sayed, A.A.; Wang, Y.; Nelson, M.E.; Thomas, C.J.; Inglese, J.; Williams, D.L.; Austin, C.P. Quantitative high-throughput screen identifies inhibitors of the Schistosoma mansoni redox cascade. PLoS Negl. Trop. Dis., 2008 2, e127.
55. Xu, J.; Arnér, E.S. Pyrroloquinoline quinone modulates the kinetic parameters of the mammalian selenoprotein thioredoxin reductase 1 and is an inhibitor of glutathione reductase. Biochem. Pharmacol., 2012 83, 815-820.
56. Theobald, A.J.; Caballero, I.; Coma, I.; Colmenarejo, G.; Cid, C.; Gamo, F.J.; Hibbs, M.J.; Bass, A.L.; Thomas, D.A. Discovery and biochemical characterization of Plasmodium thioredoxin reductase inhibitors from an antimalarial set. Biochemistry., 2012 51, 4764-4771.
57. Andricopulo, A.D.; Akoachere, M.B.; Krogh, R.; Nickel, C.; McLeish, M.J.; Kenyon, G.L.; Arscott, L.D.; Williams, C.H. Jr; Davioud-Charvet, E.; Becker K. Specific inhibitors of Plasmodium falciparum thioredoxin reductase as potential antimalarial agents. Bioorg. Med. Chem. Lett., 2006 16 (8), 2283-2292.
58. Palmer, T. Understanding enzymes, 2nd ed.; Horwood Ltd., Chichester, U.K., 1985.
59. Gromer, S.: Arscott, L.D.; Williams, C.H. Jr.; Schirmer, R.H.; Becker, K. Human placenta thioredoxin reductase. Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds. J. Biol. Chem., 1998 273, 20096-20101.
60. Deponte, M.; Urig, S.; Arscott, L.D.; Fritz-Wolf, K.; Réau, R.; Herold-Mende, C.; Koncarevic, S.; Meyer, M.; Davioud-Charvet, E.; Ballou, D.P.; Williams, C.H. Jr.; Becker, K. Mechanistic studies on a novel, highly potent gold-phosphole inhibitor of human glutathione reductase. J. Biol. Chem., 2005 280, 20628-20637.
61. Schroder, D.; Schwarz, H.; Hrusak, J.; Pyykko, P. Cationic gold (I) complexes of xenon and of ligands containing the donor atoms oxygen, nitrogen, phosphorous, and sulfur. Inorg. Chem., 1998 37, 624-632.
62. Srivastava, M.; Singh, S.; Self, W.T. Exposure to silver nanoparticles inhibits selenoprotein synthesis and the activity of thioredoxin reductase. Environ. Health Perspect., 2012 120, 56-61.
63. Mura, P.; Camalli, M.; Bindoli, A.; Sorrentino, F.; Casini, A.; Gabbiani, C.; Corsini, M.; Zanello, P.; Rigobello, M.P.; Messori, L. Activity of rat cytosolic thioredoxin reductase is strongly decreased by trans-[bis(2-amino-5methylthiazole)tetrachlororuthenate (III)]: first report of relevant thioredoxin reductase inhibition for a ruthenium compound. J. Med. Chem., 2007 50, 5871-5874.
64. Casini, A.; Gabbiani, C.; Sorrentino, F.; Rigobello, M.P.; Bindoli, A.; Geldbach, T.J.; Marrone, A.; Re, N.; Hartinger, C.G.; Dyson, P.J.; Messori, L. Emerging protein targets for anticancer metallodrugs: inhibition of thioredoxin reductase and cathepsin B by antitumor ruthenium(II)-arene compounds. J. Med. Chem., 2008 51, 6773-6781.
65. Oehninger, L.; Stefanopoulou, M.; Alborzinia, H.; Schur, J.; Ludewig, S.; Namikawa, K.; Muñoz-Castro, A.; Köster, R.W.; Baumann, K.; Wölfl, S.; Sheldrick, W.S.; Ott, I. Evaluation of arene ruthenium(II) N-heterocyclic carbene complexes as organometallics interacting with thiol and selenol containing biomolecules. Dalton Trans., 2013 42, 1657-1666.
66. Branco, V.; Canário, J.; Lu, J.; Holmgren, A.; Carvalho, C. Mercury and selenium interaction in vivo: effects on thioredoxin reductase and glutathione peroxidase. Free Radic. Biol. Med., 2012 52, 781-793.
67. Wagner, C.; Sudati, J.H.; Nogueira, C.W.; Rocha, J.B. In vivo and in vitro inhibition of mice thioredoxin reductase by methylmercury. Biometals, 2010 23, 1171-1177.
68. Carvalho, C.M.; Lu, J.; Zhang, X.; Arnér, E.S.; Holmgren, A. Effects of selenite and chelating agents on mammalian thioredoxin reductase inhibited by mercury: implications for treatment of mercury poisoning. FASEB J., 2011 25, 370-381.
69. Carvalho, C.M.; Chew, E.H.; Hashemy, S.I.; Lu, J; Holmgren, A. Inhibition of the human thioredoxin system. A molecular mechanism of mercury toxicity. J. Biol. Chem., 2008 283, 11913-11923.
70. Hondal, R.J.; Ruggles, E.L. Differing views of the role of selenium in thioredoxin reductase. Amino Acids., 2011 41, 73-89.
71. Arnér, E.S.; Björnstedt, M.; Holmgren, A. 1-Chloro-2,4-dinitrobenzene is an irreversible inhibitor of human thioredoxin reductase. Loss of thioredoxin disulfide reductase activity is accompanied by a large increase in NADPH oxidase activity. J. Biol. Chem., 1995 270, 3479-3482.
72. Nordberg, J.; Zhong, L.; Holmgren, A.; Arnér, E.S. Mammalian thioredoxin reductase is irreversibly inhibited by dinitrohalobenzenes by alkylation of both the redox active selenocysteine and its neighboring cysteine residue. J. Biol. Chem., 1998 273, 10835-10842.
73. Fang, J.; Lu, J.; Holmgren, A. Thioredoxin Reductase Is Irreversibly Modified by Curcumin. A novel molecular mechanism for its anticancer activity. J. Biol. Chem., 2005 280, 25284-25290.
74. FitzGerald, G.B.; Bauman, C.; Hussoin, M.S.; Wick, M.M. 2,4-Dihydroxybenzylamine: a specific inhibitor of glutathione reductase. Biochem. Pharmacol., 1991 41, 185-190.
75. Becker, K.; Gui, M.; Schirmer, R.H. Inhibition of human glutathione reductase by S-nitrosoglutathione. Eur. J. Biochem., 1995 234, 472-478.
76. Rai, G.; Sayed, A.A.; Lea, W.A.; Luecke, H.F.; Chakrapani, H.; Prast-Nielsen, S.; Jadhav, A.; Leister, W.; Shen, M.; Inglese, J.; Austin, C.P.; Keefer, L.; Arnér, E.S.; Simeonov, A.; Maloney, D.J.; Williams, D.L.; Thomas, C.J. Structure mechanism insights and the role of nitric oxide donation guide the development of oxadiazole-2-oxides as therapeutic agents against schistosomiasis. J. Med. Chem., 2009 52, 6474-6483.
77. Zhao, Z. Thiophosphate derivatives as inhibitors of tyrosine phosphatases. Biochem. Biophys. Res. Commun., 1996 218, 480-484.
78. Baiocco, P.; Colotti, G.; Franceschini, S.; Ilari, A. Molecular basis of antimony treatment in leishmaniasis. J. Med. Chem., 2009 52, 2603-2612.
79. Bauer, H.; Fritz-Wolf, K.; Winzer, A.; Kühner, S.; Little, S.; Yardley, V.; Vezin, H.; Palfey, B.; Schirmer, R.H.; Davioud-Charvet, E. A fluoro analogue of the menadione derivative 6-[2'-(3'-methyl)-1',4'-naphthoquinolyl]hexanoic acid is a suicide substrate of glutathione reductase. Crystal structure of the alkylated human enzyme. J. Am. Chem. Soc., 2006 128, 10784-10794.
80. Hill, D.T.; Isab, A.A.; Griswold, D.E.; DiMartino, M.J.; Matz, E.D.; Figueroa, A.L.; Wawro, J.E.; DeBrosse, C.; Reiff, W.M.; Elder, R.C.; Jones, B.; Webb, J.W.; Shaw, C.F. Seleno-auranofin (Et3PAuSe-tagl): synthesis, spectroscopic (EXAFS, 197Au Mössbauer, 31P, 1H, 13C, and 77Se NMR, ESI-MS) characterization, biological activity, and rapid serum albumin-induced triethylphosphine oxide generation. Inorg. Chem., 2010 49, 7663-7675.
81. Shaw, C.F. Gold-based therapeutic agents. Chem. Rev., 1999 99, 2589-2600.
82. Schallreuter, K.U.; Wood, J.M. Azelaic acid as a competitive inhibitor of thioredoxin reductase in human melanoma cells. Cancer Lett., 1994 36, 297-305.
83. Gromer, S.; Gross, J.H. Methylseleninate is a substrate rather than an inhibitor of mammalian thioredoxin reductase. Implications for the antitumor effects of selenium. J. Biol. Chem., 2002 277, 9701-9706.
84. Shi, C.; Yu, L.; Yang, F.; Yan, J.; Zeng, H. A novel organoselenium compound induces cell cycle arrest and apoptosis in prostate cancer cell lines. Biochem. Biophys. Res. Commun., 2003 309, 578-583.
85. Zhao, R.; Masayasu, H.; Holmgren, A. Ebselen: a substrate for human thioredoxin reductase strongly stimulating its hydroperoxide reductase activity and a superfast thioredoxin oxidant. Proc. Natl. Acad. Sci. U. S. A., 2002 99, 8579-8584.
86. Jan, Y.H.; Heck, D.E.; Gray, J.P.; Zheng, H.; Casillas, R.P.; Laskin, D.L.; Laskin, J.D. Selective targeting of selenocysteine in thioredoxin reductase by the half mustard 2-chloroethyl ethyl sulfide in lung epithelial cells. Chem. Res. Toxicol., 2010 23, 1045-1053.
87. Waley, S.G. Kinetics of suicide substrates. Biochem. J., 1985 227, 843-849.
88. Walsh, C. Suicide substrates, mechanism-based enzyme inactivators: recent developments. Annu. Rev. Biochem., 1984 53, 493-535.
89. Fersht, A. Enzyme structure and mechanism, 2nd ed.; W.H. Freeman, New York. 1984.
90. Karplus, P.A.; Pai, E.F.; Schulz, G.E. A crystallographic study of the glutathione binding site of glutathione reductase at 0.3-nm resolution. Eur. J. Biochem., 1989 178, 693-703.
91. Lüönd, R.M.; McKie, J.H.; Douglas, K.T.; Dascombe, M.J.; Vale, J. Inhibitors of glutathione reductase as potential antimalarial drugs. Kinetic cooperativity and effect of dimethyl sulphoxide on inhibition kinetics. J. Enzyme Inhib., 1998 13, 327-345.
92. Colotti, G.; Ilari, A.; Fiorillo, A.; Baiocco, P.; Cinellu, M.A.; Maiore, L.; Scaletti, F.; Gabbiani, C.; Messori, L. Metal-Based Compounds as Prospective Antileishmanial Agents: Inhibition of Trypanothione Reductase by Selected Gold Complexes. ChemMedChem., 2013. [Epub ahead of print]
93. Omata, Y.; Folan, M.; Shaw, M.; Messer, R.L.; Lockwood, P.E.; Hobbs, D.; Bouillaguet, S.; Sano, H.; Lewis, J.B.; Wataha, J.C. Sublethal concentrations of diverse gold compounds inhibit mammalian cytosolic thioredoxin reductase (TrxR1). Toxicol. In Vitro. 2006, 20, 882-890.
94. Viry, E.; Battaglia, E.; Deborde, V.; Muller, T.; Reau, R.; Davioud-Charvet, E.; Bagrel, D. A Sugar-modified phosphole gold complex with antiproliferative properties acting as a thioredoxin reductase inhibitor in MCF-7 cells. ChemMedChem., 2008 3, 1667-1670.
95. Urig, S.; Fritz-Wolf, K.; Réau, R.; Herold-Mende, C.; Tóth, K.; Davioud-Charvet, E.; Becker, K. Undressing of phosphine gold(I) complexes as irreversible inhibitors of human disulfide reductases. Angew. Chem. Int. Ed. Engl., 2006 45, 1881-1886.
96. Ott, I.; Qian, X.; Xu, Y.; Vlecken, D.H.; Marques, I.J.; Kubutat, D.; Will, J.; Sheldrick, W.S.; Jesse, P.; Prokop, A.; Bagowski, C.P. A gold(I) phosphine complex containing a naphthalimide ligand functions as a TrxR inhibiting antiproliferative agent and angiogenesis inhibitor. J. Med. Chem., 2009 52, 763-770.
97. Schuh, E.; Pflüger, C.; Citta, A.; Folda, A.; Rigobello, M.P.; Bindoli, A.; Casini, A.; Mohr, F. Gold(I) carbene complexes causing thioredoxin 1 and thioredoxin 2 oxidation as potential anticancer agents. J. Med. Chem., 2012 55, 5518-5528.
98. Saggioro, D.; Rigobello, M.P.; Paloschi, L.; Folda, A.; Moggach, S.A.; Parsons, S.; Ronconi, L.; Fregona, D.; Bindoli, A. Gold(III)-dithiocarbamato complexes induce cancer cell death triggered by thioredoxin redox system inhibition and activation of ERK pathway. Chem. Biol., 2007 14, 1128-1139.
99. Baiocco, P.; Ilari, A.; Ceci, P.; Orsini, S.; Gramiccia, M.; Di Muccio, T.; Colotti, G. Inhibitory Effect of Silver Nanoparticles on Trypanothione Reductase Activity and Leishmania infantum Proliferation. Med. Chem. Lett., 2011 2, 230-233.
100. Becker. K.; Herold-Mende, C.; Park, J.J.; Lowe, G.; Schirmer, R.H. Human thioredoxin reductase is efficiently inhibited by (2,2':6',2' '-terpyridine)platinum(II) complexes. Possible implications for a novel antitumor strategy. J. Med. Chem., 2001 44, 2784-2792.
101. Lo, Y.C.; Ko, T.P.; Su, W.C.; Su, T.L.; Wang, A.H. Terpyridineplatinum(II) complexes are effective inhibitors of mammalian topoisomerases and human thioredoxin reductase 1. J. Inorg. Biochem., 2009 103, 1082-1092.
102. Arnér, E.S.; Nakamura, H.; Sasada, T.; Yodoi, J.; Holmgren, A.; Spyrou, G. Analysis of the inhibition of mammalian thioredoxin, thioredoxin reductase, and glutaredoxin by cis-diamminedichloroplatinum (II) and its major metabolite, the glutathione-platinum complex. Free Radic. Biol. Med., 2001 31, 1170-1178.
103. Witte, A.B.; Anestål, K.; Jerremalm, E.; Ehrsson, H.; Arnér, E.S. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds. Free Radic. Biol. Med., 2005 39, 696-703.
104. Hashemy, S.I.; Ungerstedt, J.S.; Zahedi Avval, F.; Holmgren, A. Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase. J. Biol. Chem., 2006 281, 10691-10697.
105. Lu, J.; Chew, E.H.; Holmgren, A. Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc. Natl. Acad. Sci. U. S. A., 2007 104, 12288-12293.
106. Lin, S.; Del Razo, L.M.; Styblo, M.; Wang, C.; Cullen, W.R.; Thomas, D.J. Arsenicals inhibit thioredoxin reductase in cultured rat hepatocytes. Chem. Res. Toxicol., 2001 14, 305-311.
107. Schallreuter, K.U.; Wood, J.M. The stereospecific suicide inhibition of human melanoma thioredoxin reductase by 13-cis retinoic acid. Biochem. Biophys. Res. Comm., 1989 160, 573-579.
108. Saravanamuthu, A.; Vickers, T.J.; Bond, C.S.; Peterson, M.R.; Hunter, W.N.; Fairlamb, A.H. Two interacting binding sites for quinacrine derivatives in the active site of trypanothione reductase: a template for drug design. J. Biol. Chem., 2004 279, 29493-29500.
109. Gallwitz, H.; Bonse, S.; Martinez-Cruz, A.; Schlichting, I.; Schumacher, K.; Krauth-Siegel, R.L. Ajoene is an inhibitor and subversive substrate of human glutathione reductase and Trypanosoma cruzi trypanothione reductase: crystallographic, kinetic, and spectroscopic studies. J. Med. Chem., 1999 42, 364-372.
110. Li, S.; Zhang, J.; Li, J.; Chen, D.; Matteucci, M.; Curd, J.; Duan, J.X. Inhibition of both thioredoxin reductase and glutathione reductase may contribute to the anticancer mechanism of TH-302. Biol. Trace Elem. Res., 2010 136, 294-301.
111. Lu, J.; Chew, E.H.; Holmgren, A. Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc. Natl. Acad. Sci. U. S. A., 2007 104, 12288-12293.
112. Savvides, S.N.; Scheiwein, M.; Bohme, C.C.; Arteel, G.E.; Karplus, P.A.; Becker, K.; Schirmer, R.H. Crystal structure of the antioxidant enzyme glutathione reductase inactivated by peroxynitrite. J. Biol. Chem., 2002 277, 2779-2784.
113. Becker, K.; Savvides, S.N.; Keese, M.; Schirmer, R.H.; Karplus, P.A. Enzyme inactivation through sulfhydryl oxidation by physiologic NO-carriers. Nat. Struct. Biol., 1998 5, 267-271.